Plus Therapeutics to Host Key Opinion Leader Roundtable on ReSPECT-GBM Trial (PRNewswire) - Nov 3, 2021 - "Plus Therapeutics, Inc...announced that it will host a key opinion leader roundtable discussion on the ReSPECT-GBM trial on Thursday, November 18, 2021, 4:00 to 5:00 p.m. ET. The webinar will feature a comprehensive discussion about the ongoing ReSPECT-GBM trial including key safety, tolerability, dosing, feasibility and efficacy data....The ReSPECT-GBM Phase 1 clinical trial is evaluating the Company's lead investigational asset, Rhenium-186 NanoLiposome (186RNL), in patients with recurrent glioblastoma (GBM). Dr. Brenner will also present ReSPECT-GBM data during a poster session on November 19, 2021, 7:30 – 9:30 p.m. ET, at the 2021 Society for Neuro-Oncology Annual Meeting and Education Day being held in Boston, Massachusetts."
P1/2 data • Glioblastoma • Oncology
|